NCT02026271 - A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

August 31, 2019

Study Completion Date

August 31, 2019

Conditions

Glioblastoma MultiformeAnaplastic Oligoastrocytoma

Interventions

BIOLOGICAL

Ad-RTS-hIL-12

"* 2.0 x 10\^11 viral particles (vp) per injection or 1.0 x 10\^12 viral particles (vp) per injection~* one intratumoral injection of Ad-RTS-hIL-12"

DRUG

veledimex

"* 4 doses (20mg/day, 40mg/day, 80mg/day, and 120mg/day)~* 14 oral daily doses of veledimex~* 1 Expansion cohort at a single dose level at or below MTD"

Trial Locations (6)

60611

Northwestern, Chicago

60637

University of Chicago, Chicago

77030

MD Anderson Cancer Center, Houston

90048

Cedars-Sinai, Los Angeles

94143

University of California - San Francisco, San Francisco

02115

Brigham & Women's, Boston